ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
ARROWHEAD PHARMACEUTICALS, INC.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$57.23+1.33 (+2.38%)
Close on Oct 19, 2026
- Market cap
- $8.21B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$20.42 (+55.47%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ARROWHEAD PHARMACEUTICALS, INC. grew revenue 16.8% to $669.50M over the twelve months to Jun 30, 2026. Free cash flow was -$75.11M.
Revenue
$669.50M
+16.8% vs. a year earlier
Operating income
-$226.44M
TTM Q3 2026
Free cash flow
-$75.11M
TTM Q3 2026
EPS, diluted
-$2.25
TTM Q3 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $8.21B
- P/E ratio
- –
- Price to sales
- 12.26
- Price to book
- 17.63
- Dividend yield
- –
- Free cash flow yield
- -0.92%
Fundamentals
- Revenue
- $669.50M
- Net income
- -$319.95M
- EPS, diluted
- -$2.25
- Free cash flow
- -$75.11M
- Book value per share
- $3.25
- Diluted shares
- 143M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$669.50M+16.8% YoY
Operating income
-$226.44M
Net income
-$319.95M
EPS, diluted
-$2.25
Free cash flow
-$75.11M
Reported periodTrailing twelve months